메뉴 건너뛰기




Volumn 36, Issue 10, 2015, Pages 1163-1169

Toward rapamycin analog (rapalog)-based precision cancer therapy

Author keywords

mTOR; precision cancer therapy; rapalog; rapamycin

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DALOTUZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NAVELBINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRAMETINIB; TRASTUZUMAB; ANTINEOPLASTIC ANTIBIOTIC; TARGET OF RAPAMYCIN KINASE;

EID: 84943270672     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.68     Document Type: Review
Times cited : (112)

References (55)
  • 1
    • 67349217986 scopus 로고    scopus 로고
    • Molecular mechanisms of mTOR-mediated translational control
    • Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 30-18.
    • (2009) Nat Rev Mol Cell Biol , vol.10 , pp. 30-18
    • Ma, X.M.1    Blenis, J.2
  • 2
    • 67349241955 scopus 로고    scopus 로고
    • DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
    • Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
    • (2009) Cell , vol.137 , pp. 873-886
    • Peterson, T.R.1    Laplante, M.2    Thoreen, C.C.3    Sancak, Y.4    Kang, S.A.5    Kuehl, W.M.6
  • 3
    • 0037178781 scopus 로고    scopus 로고
    • Raptor a binding partner of target of rapamycin (TOR) mediates TOR action
    • Hara K, Maruki Y, Long XM, Yoshino K, Oshiro N, Hidayat S, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-89.
    • (2002) Cell , vol.110 , pp. 177-189
    • Hara, K.1    Maruki, Y.2    Long, X.M.3    Yoshino, K.4    Oshiro, N.5    Hidayat, S.6
  • 4
    • 3342895823 scopus 로고    scopus 로고
    • Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
    • Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302.
    • (2004) Curr Biol , vol.14 , pp. 1296-1302
    • Sarbassov, D.D.1    Ali, S.M.2    Kim, D.H.3    Guertin, D.A.4    Latek, R.R.5    Erdjument-Bromage, H.6
  • 5
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3    Dutcher, J.4    Figlin, R.5    Kapoor, A.6
  • 6
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3    Hutson, T.E.4    Porta, C.5    Bracarda, S.6
  • 7
    • 77955430762 scopus 로고    scopus 로고
    • Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
    • Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010; 20: 4308-12.
    • (2010) Bioorg Med Chem Lett , vol.20 , pp. 4308-4312
    • Garcia-Echeverria, C.1
  • 8
    • 84863116501 scopus 로고    scopus 로고
    • MTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors
    • Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell cycle 2012; 11: 594-603.
    • (2012) Cell Cycle , vol.11 , pp. 594-603
    • Zhang, Y.1    Zheng, X.F.2
  • 9
    • 78650929230 scopus 로고    scopus 로고
    • Recent clinical trials of mTOR-targeted cancer therapies
    • Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6: 24-35.
    • (2011) Rev Recent Clin Trials , vol.6 , pp. 24-35
    • Don, A.S.1    Zheng, X.F.2
  • 10
    • 84898989382 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: Reasons for phase III failure and novel perspectives on trial design
    • Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072-9.
    • (2014) Clin Cancer Res , vol.20 , pp. 2072-2079
    • Llovet, J.M.1    Hernandez-Gea, V.2
  • 11
    • 79952108510 scopus 로고    scopus 로고
    • Oncogenic mutations of PIK3CA in human cancers
    • Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 2010; 347: 21-41.
    • (2010) Curr Top Microbiol Immunol , vol.347 , pp. 21-41
    • Samuels, Y.1    Waldman, T.2
  • 12
    • 79960732694 scopus 로고    scopus 로고
    • PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
    • Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30: 3222-33.
    • (2011) Oncogene , vol.30 , pp. 3222-3233
    • Weigelt, B.1    Warne, P.H.2    Downward, J.3
  • 13
    • 77955288855 scopus 로고    scopus 로고
    • Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
    • Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858-66.
    • (2010) J Clin Invest , vol.120 , pp. 2858-2866
    • Di Nicolantonio, F.1    Arena, S.2    Tabernero, J.3    Grosso, S.4    Molinari, F.5    Macarulla, T.6
  • 14
    • 84893764401 scopus 로고    scopus 로고
    • Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
    • Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 2014; 120: 603-10.
    • (2014) Cancer , vol.120 , pp. 603-610
    • Mackay, H.J.1    Eisenhauer, E.A.2    Kamel-Reid, S.3    Tsao, M.4    Clarke, B.5    Karakasis, K.6
  • 15
    • 0036735346 scopus 로고    scopus 로고
    • Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779
    • Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62: 5027-34.
    • (2002) Cancer Res , vol.62 , pp. 5027-5034
    • Shi, Y.1    Gera, J.2    Hu, L.3    Hsu, J.H.4    Bookstein, R.5    Li, W.6
  • 16
    • 33747874283 scopus 로고    scopus 로고
    • Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo
    • Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006; 66: 7639-46.
    • (2006) Cancer Res , vol.66 , pp. 7639-7646
    • Wendel, H.G.1    Malina, A.2    Zhao, Z.3    Zender, L.4    Kogan, S.C.5    Cordon-Cardo, C.6
  • 17
    • 52449131427 scopus 로고    scopus 로고
    • PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel
    • Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, et al. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 2008; 14: 3993-4001.
    • (2008) Clin Cancer Res , vol.14 , pp. 3993-4001
    • Yang, L.1    Clarke, M.J.2    Carlson, B.L.3    Mladek, A.C.4    Schroeder, M.A.5    Decker, P.6
  • 18
    • 84864369495 scopus 로고    scopus 로고
    • Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers
    • Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23: 2663-70.
    • (2012) Ann Oncol , vol.23 , pp. 2663-2670
    • Seront, E.1    Rottey, S.2    Sautois, B.3    Kerger, J.4    D'Hondt, L.A.5    Verschaeve, V.6
  • 19
    • 84884592636 scopus 로고    scopus 로고
    • PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
    • Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer 2013; 109: 1586-92.
    • (2013) Br J Cancer , vol.109 , pp. 1586-1592
    • Seront, E.1    Pinto, A.2    Bouzin, C.3    Bertrand, L.4    Machiels, J.P.5    Feron, O.6
  • 20
    • 1642535431 scopus 로고    scopus 로고
    • AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
    • Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737-46.
    • (2004) J Biol Chem , vol.279 , pp. 2737-2746
    • Gera, J.F.1    Mellinghoff, I.K.2    Shi, Y.3    Rettig, M.B.4    Tran, C.5    Hsu, J.H.6
  • 22
    • 63149143885 scopus 로고    scopus 로고
    • AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001
    • Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 2009; 15: 1277-87.
    • (2009) Clin Cancer Res , vol.15 , pp. 1277-1287
    • Marinov, M.1    Ziogas, A.2    Pardo, O.E.3    Tan, L.T.4    Dhillon, T.5    Mauri, F.A.6
  • 23
    • 34147104488 scopus 로고    scopus 로고
    • AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells
    • Frost P, Shi Y, Hoang B, Lichtenstein A. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007; 26: 2255-62.
    • (2007) Oncogene , vol.26 , pp. 2255-2262
    • Frost, P.1    Shi, Y.2    Hoang, B.3    Lichtenstein, A.4
  • 24
    • 35348858663 scopus 로고    scopus 로고
    • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
    • Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 379-85.
    • (2007) Clin Genitourin Cancer , vol.5 , pp. 379-385
    • Cho, D.1    Signoretti, S.2    Dabora, S.3    Regan, M.4    Seeley, A.5    Mariotti, M.6
  • 28
    • 84878357685 scopus 로고    scopus 로고
    • A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1
    • Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013; 340: 1100-6.
    • (2013) Science , vol.340 , pp. 1100-1106
    • Bar-Peled, L.1    Chantranupong, L.2    Cherniack, A.D.3    Chen, W.W.4    Ottina, K.A.5    Grabiner, B.C.6
  • 29
    • 0028825698 scopus 로고
    • TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin
    • Lorenz MC, Heitman J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J Biol Chem 1995; 270: 27531-7.
    • (1995) J Biol Chem , vol.270 , pp. 27531-27537
    • Lorenz, M.C.1    Heitman, J.2
  • 30
    • 77952243626 scopus 로고    scopus 로고
    • Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
    • Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010; 29: 2746-52.
    • (2010) Oncogene , vol.29 , pp. 2746-2752
    • Sato, T.1    Nakashima, A.2    Guo, L.3    Coffman, K.4    Tamanoi, F.5
  • 31
    • 84899678098 scopus 로고    scopus 로고
    • A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity
    • Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 2014; 4: 554-63.
    • (2014) Cancer Discov , vol.4 , pp. 554-563
    • Grabiner, B.C.1    Nardi, V.2    Birsoy, K.3    Possemato, R.4    Shen, K.5    Sinha, S.6
  • 32
    • 84899680978 scopus 로고    scopus 로고
    • Activating mTOR mutations in a patient with an extraordinary response on a phase i trial of everolimus and pazopanib
    • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014; 4: 546-53.
    • (2014) Cancer Discov , vol.4 , pp. 546-553
    • Wagle, N.1    Grabiner, B.C.2    Van Allen, E.M.3    Hodis, E.4    Jacobus, S.5    Supko, J.G.6
  • 33
    • 34247127783 scopus 로고    scopus 로고
    • Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer
    • Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett 2007; 251: 105-13.
    • (2007) Cancer Lett , vol.251 , pp. 105-113
    • Nozawa, H.1    Watanabe, T.2    Nagawa, H.3
  • 34
    • 23944453425 scopus 로고    scopus 로고
    • Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study
    • Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23: 5294-304.
    • (2005) J Clin Oncol , vol.23 , pp. 5294-5304
    • Galanis, E.1    Buckner, J.C.2    Maurer, M.J.3    Kreisberg, J.I.4    Ballman, K.5    Boni, J.6
  • 35
    • 39749126103 scopus 로고    scopus 로고
    • Phospho-S6 ribosomal protein: A potential new predictive sarcoma marker for targeted mTOR therapy
    • Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 21: 231-7.
    • (2008) Mod Pathol , vol.21 , pp. 231-237
    • Iwenofu, O.H.1    Lackman, R.D.2    Staddon, A.P.3    Goodwin, D.G.4    Haupt, H.M.5    Brooks, J.S.6
  • 36
    • 33750089285 scopus 로고    scopus 로고
    • Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer
    • Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006; 107: 1801-11.
    • (2006) Cancer , vol.107 , pp. 1801-1811
    • Castellvi, J.1    Garcia, A.2    Rojo, F.3    Ruiz-Marcellan, C.4    Gil, A.5    Baselga, J.6
  • 37
    • 66949159435 scopus 로고    scopus 로고
    • Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: Association with stage and grade in vivo and link with response to rapamycin treatment in vitro
    • Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Muller B, et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009; 135: 933-41.
    • (2009) J Cancer Res Clin Oncol , vol.135 , pp. 933-941
    • Darb-Esfahani, S.1    Faggad, A.2    Noske, A.3    Weichert, W.4    Buckendahl, A.C.5    Muller, B.6
  • 38
    • 68949102180 scopus 로고    scopus 로고
    • Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
    • Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-9.
    • (2009) J Clin Oncol , vol.27 , pp. 3822-3829
    • Hess, G.1    Herbrecht, R.2    Romaguera, J.3    Verhoef, G.4    Crump, M.5    Gisselbrecht, C.6
  • 39
    • 23944481410 scopus 로고    scopus 로고
    • Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    • Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-56.
    • (2005) J Clin Oncol , vol.23 , pp. 5347-5356
    • Witzig, T.E.1    Geyer, S.M.2    Ghobrial, I.3    Inwards, D.J.4    Fonseca, R.5    Kurtin, P.6
  • 40
    • 30044432434 scopus 로고    scopus 로고
    • Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
    • Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-7.
    • (2006) Nat Med , vol.12 , pp. 122-127
    • Thomas, G.V.1    Tran, C.2    Mellinghoff, I.K.3    Welsbie, D.S.4    Chan, E.5    Fueger, B.6
  • 41
    • 77951877765 scopus 로고    scopus 로고
    • Alterations in VHL as potential biomarkers in renal-cell carcinoma
    • Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010; 7: 277-88.
    • (2010) Nat Rev Clin Oncol , vol.7 , pp. 277-288
    • Gossage, L.1    Eisen, T.2
  • 42
    • 68549092780 scopus 로고    scopus 로고
    • Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha
    • Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009; 115: 3651-60.
    • (2009) Cancer , vol.115 , pp. 3651-3660
    • Figlin, R.A.1    De Souza, P.2    McDermott, D.3    Dutcher, J.P.4    Berkenblit, A.5    Thiele, A.6
  • 43
    • 77956411746 scopus 로고    scopus 로고
    • Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer
    • Chen G, Yang N, Wang X, Zheng SY, Chen Y, Tong LJ, et al. Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer. J Mol Med (Berl) 2010; 88: 941-52.
    • (2010) J Mol Med (Berl) , vol.88 , pp. 941-952
    • Chen, G.1    Yang, N.2    Wang, X.3    Zheng, S.Y.4    Chen, Y.5    Tong, L.J.6
  • 44
    • 84875772605 scopus 로고    scopus 로고
    • Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models
    • Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, Seidler B, et al. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget 2013; 4: 277-88.
    • (2013) Oncotarget , vol.4 , pp. 277-288
    • Diersch, S.1    Wenzel, P.2    Szameitat, M.3    Eser, P.4    Paul, M.C.5    Seidler, B.6
  • 45
    • 78751693800 scopus 로고    scopus 로고
    • Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    • Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010; 2: 53.
    • (2010) Genome Med , vol.2 , pp. 53
    • Swanton, C.1    Larkin, J.M.2    Gerlinger, M.3    Eklund, A.C.4    Howell, M.5    Stamp, G.6
  • 46
    • 56249147509 scopus 로고    scopus 로고
    • Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
    • Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105: 17414-9.
    • (2008) Proc Natl Acad Sci USA , vol.105 , pp. 17414-17419
    • Choo, A.Y.1    Yoon, S.O.2    Kim, S.G.3    Roux, P.P.4    Blenis, J.5
  • 47
    • 32944457518 scopus 로고    scopus 로고
    • MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    • O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-8.
    • (2006) Cancer Res , vol.66 , pp. 1500-1508
    • O'Reilly, K.E.1    Rojo, F.2    She, Q.-B.3    Solit, D.4    Mills, G.B.5    Smith, D.6
  • 48
    • 59749091850 scopus 로고    scopus 로고
    • A complex interplay between Akt TSC2, and the two mTOR complexes
    • Huang J, Manning BD. A complex interplay between Akt, TSC2, and the two mTOR complexes. Biochem Soc Trans 2009; 37: 217.
    • (2009) Biochem Soc Trans , vol.37 , pp. 217
    • Huang, J.1    Manning, B.D.2
  • 49
    • 77649268890 scopus 로고    scopus 로고
    • Inhibitors of the PI3K/Akt/mTOR pathway: New hope for breast cancer patients
    • Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov 2010; 5: 29-57.
    • (2010) Recent Pat Anticancer Drug Discov , vol.5 , pp. 29-57
    • Ghayad, S.E.1    Cohen, P.A.2
  • 50
    • 33845227643 scopus 로고    scopus 로고
    • Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors
    • Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-84.
    • (2006) Mol Cancer Ther , vol.5 , pp. 2676-2684
    • Buck, E.1    Eyzaguirre, A.2    Brown, E.3    Petti, F.4    McCormack, S.5    Haley, J.D.6
  • 51
    • 84899057121 scopus 로고    scopus 로고
    • Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
    • Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res 2014; 16: R32.
    • (2014) Breast Cancer Res , vol.16 , pp. R32
    • Singh, J.1    Novik, Y.2    Stein, S.3    Volm, M.4    Meyers, M.5    Smith, J.6
  • 52
    • 84899992665 scopus 로고    scopus 로고
    • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial
    • Andre F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 580-91.
    • (2014) Lancet Oncol , vol.15 , pp. 580-591
    • Andre, F.1    O'Regan, R.2    Ozguroglu, M.3    Toi, M.4    Xu, B.5    Jerusalem, G.6
  • 53
    • 84933502992 scopus 로고    scopus 로고
    • Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors
    • Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, et al. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol 2015; 33:1551-6.
    • (2015) J Clin Oncol , vol.33 , pp. 1551-1556
    • Hobday, T.J.1    Qin, R.2    Reidy-Lagunes, D.3    Moore, M.J.4    Strosberg, J.5    Kaubisch, A.6
  • 54
    • 77149133090 scopus 로고    scopus 로고
    • AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma
    • Huynh H. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Cancer 2010; 116: 1315-25.
    • (2010) Cancer , vol.116 , pp. 1315-1325
    • Huynh, H.1
  • 55
    • 84922515314 scopus 로고    scopus 로고
    • A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
    • Tolcher AW, Bendell JC, Papadopoulos KP, Burris HA, 3rd, Patnaik A, Jones SF, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol 2015; 26: 58-64.
    • (2015) Ann Oncol , vol.26 , pp. 58-64
    • Tolcher, A.W.1    Bendell, J.C.2    Papadopoulos, K.P.3    Burris, H.A.4    Patnaik, A.5    Jones, S.F.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.